Czech Republic PharmaBoardroom’s latest report: Healthcare & Life Sciences Review: Czech Republic is available for download now.   Home to a USD 3.38 billion pharma market, one of Central and Eastern Europe’s most high-performing healthcare systems, and one of the region’s leading economies, the Czech Republic’s healthcare and life sciences market is…

Brazil Below we highlight recent news in Brazilian pharma, including the impact of coronavirus as well as legal and regulatory updates.    Proposal to allow breaking of patents due to Covid-19 A proposal has been made to amend an intellectual property law, adding a clause on allowing compulsory licenses and breaking…

Coronavirus With the global coronavirus pandemic still ongoing and teleworking having become the new normal, pharma executives from across the world are giving us their insights into how they are managing in the age of confinement to ensure continued employee welfare and the safe supply of medications to the patients and…

USA Indian firm Biocon has seen great success in the US in recent years, with two biosimilar launches and a range of generic medicines now available on the American market.   In a recent interview with PharmaBoardroom, Biocon’s Commercial Head Global Generics & SVP Marketing Abhijit Zutshi outlined the company’s recipe…

Coronavirus Sophia Ononye-Onyia outlines the key failings in the USA’s response to the coronavirus outbreak and why greater numbers of inter-industry partnerships and increased technological uptake are key to fighting this crisis and reframing the US life sciences industry of the future.   Imagine if we invested billions in epidemiological surveillance…

Belgium In 2020 PharmaBoardroom sat down with several key stakeholders in Belgian pharma to discuss company strategy, the Belgian healthcare landscape at large, and the country’s role within the wider European and global ecosystem. Here we highlight some of the key themes of the discussions: innovation, generics and biosimilars, and teamwork.…

Romania According to a 2015 United Nations International Migration Report, since Romania joined the European Union in 2007, around 3.4 million Romanians have left the country in search of a better quality of life and economic opportunity.   In 2019, the number of babies born in Romania was approximately 182,000, making…

Romania While the dismal regulatory environment in Romania has negatively affected the innovators with the uncertain and lengthy regulatory approval timelines as well as the dreaded ‘clawback tax’ doubling over the past decade, the generics sector has argued that they are the ones that have borne the brunt of unfavourable industry…

South Korea South Korea is the 12th largest healthcare market globally with a market size of around USD 20 billion in 2019. With the government’s plans to invest over USD 1.7 billion in its biopharma and biotech sectors over the next five years, the country’s prominence in the global biopharma landscape will…

Opinion Song Ruilin, chairman of the China Pharmaceutical Innovation and Research Development Association (PhIRDA) highlights the leaps and bounds with which the Chinese pharmaceutical industry has developed in recent years, the country’s increasingly important role in the global innovation landscape, and why cross-border collaboration is more crucial than ever in the…

Opinion John G. Singer examines how the ongoing coronavirus pandemic may create a new dichotomy for global healthcare – and why pharma companies still wedded to the market models of the past risk getting left behind.   “Drug” companies have a unique opportunity to invent a different market for themselves. It…

UAE PharmaBoardroom’s latest country report gives an up-to-date and comprehensive overview of one of the most strategic and innovation-friendly nations on earth: The UAE.   The UAE’s pharma market was predicted to grow to USD four billion in 2020, representing a CAGR of 8.5 percent from 2019. The country sits at…